UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Baranova A
(2023)
A phenome-wide investigation of risk factors for severe COVID-19.
in Journal of medical virology
Manousaki D
(2020)
A Polygenic Risk Score as a Risk Factor for Medication-Associated Fractures.
in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
Herranen P
(2022)
A Polygenic Risk Score for Hand Grip Strength Predicts Muscle Strength and Proximal and Distal Functional Outcomes among Older Women.
in Medicine and science in sports and exercise
Lu T
(2021)
A Polygenic Risk Score to Predict Future Adult Short Stature Among Children.
in The Journal of clinical endocrinology and metabolism
De Vincentis A
(2022)
A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.
in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Avinun R
(2019)
A polygenic score for body mass index is associated with depressive symptoms via early life stress: Evidence for gene-environment correlation.
in Journal of psychiatric research
Steinbrenner I
(2023)
A polygenic score for reduced kidney function and adverse outcomes in a cohort with chronic kidney disease.
in Kidney international
Marderstein AR
(2021)
A polygenic-score-based approach for identification of gene-drug interactions stratifying breast cancer risk.
in American journal of human genetics
Klyosova E
(2022)
A Polymorphism in the Gene Encoding Heat Shock Factor 1 (HSF1) Increases the Risk of Type 2 Diabetes: A Pilot Study Supports a Role for Impaired Protein Folding in Disease Pathogenesis.
in Life (Basel, Switzerland)
Blauwendraat C
(2021)
A population scale analysis of rare SNCA variation in the UK Biobank.
in Neurobiology of disease
Lu B
(2022)
A practical Alzheimer's disease classifier via brain imaging-based deep learning on 85,721 samples
in Journal of Big Data
Vlasschaert C
(2023)
A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic datasets
in Blood
Pärna K
(2022)
A Principal Component Informed Approach to Address Polygenic Risk Score Transferability Across European Cohorts
in Frontiers in Genetics
Xia X
(2022)
A Prism Vote method for individualized risk prediction of traits in genotype data of Multi-population.
in PLoS genetics
Zakeri A
(2022)
A probabilistic deep motion model for unsupervised cardiac shape anomaly assessment.
in Medical image analysis
Creed JH
(2020)
A prospective study of coffee and tea consumption and the risk of glioma in the UK Biobank.
in European journal of cancer (Oxford, England : 1990)
Cote DJ
(2021)
A prospective study of inflammatory biomarkers and growth factors and risk of glioma in the UK Biobank.
in Cancer epidemiology
Takeuchi H
(2022)
A Prospective Study on the Relationship Between Driving and Non-occupational Computer Use With Risk of Dementia.
in Frontiers in aging neuroscience
Takeuchi H
(2022)
A Prospective Study on the Relationship between Iron Supplement Intake, Hemoglobin Concentration, and Risk of Parkinsonism.
in Nutrients
Liu H
(2022)
A putative causality of vitamin D in common diseases: A mendelian randomization study.
in Frontiers in nutrition
Fürtjes AE
(2023)
A quantified comparison of cortical atlases on the basis of trait morphometricity.
in Cortex; a journal devoted to the study of the nervous system and behavior
Miao J
(2022)
A quantile integral linear model to quantify genetic effects on phenotypic variability.
in Proceedings of the National Academy of Sciences of the United States of America
Seidelin AS
(2022)
A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population.
in Hepatology international
Van De Weijer MP
(2022)
A Re-evaluation of Candidate Gene Studies for Well-Being in Light of Genome-Wide Evidence.
in Journal of happiness studies
Jiang L
(2019)
A resource-efficient tool for mixed model association analysis of large-scale data.
in Nature genetics
Tang M
(2022)
A review of SNP heritability estimation methods.
in Briefings in bioinformatics
Hecker J
(2022)
A robust and adaptive framework for interaction testing in quantitative traits between multiple genetic loci and exposure variables.
in PLoS genetics
Frazier-Logue N
(2022)
A Robust Modular Automated Neuroimaging Pipeline for Model Inputs to TheVirtualBrain.
in Frontiers in neuroinformatics
Gamache I
(2021)
A sex-specific evolutionary interaction between ADCY9 and CETP.
in eLife
Kim SK
(2023)
A shared genetic architecture between adhesive capsulitis and Dupuytren disease.
in Journal of shoulder and elbow surgery
Farrell S
(2023)
A Shared Genetic Signature for Common Chronic Pain Conditions and its Impact on Biopsychosocial Traits
in The Journal of Pain
Barton AR
(2022)
A spectrum of recessiveness among Mendelian disease variants in UK Biobank.
in American journal of human genetics
Klinkhammer H
(2022)
A statistical boosting framework for polygenic risk scores based on large-scale genotype data.
in Frontiers in genetics
Wang C
(2022)
A study of factors impacting disease based on the Charlson Comorbidity Index in UK Biobank.
in Frontiers in public health
Yu X
(2022)
A suggested shared aetiology of dementia - a colocalization study
in Neurobiology of Aging
Majumdar A
(2022)
A summary-statistics-based approach to examine the role of serotonin transporter promoter tandem repeat polymorphism in psychiatric phenotypes.
in European journal of human genetics : EJHG
Garcia-Etxebarria K
(2022)
A survey of functional dyspepsia in 361,360 individuals: Phenotypic and genetic cross-disease analyses.
in Neurogastroenterology and motility
Saurabh R
(2022)
A survey of genome-wide association studies, polygenic scores and UK Biobank highlights resources for autoimmune disease genetics
in Frontiers in Immunology
Battineni G
(2022)
A Survey on the Role of Artificial Intelligence in Biobanking Studies: A Systematic Review.
in Diagnostics (Basel, Switzerland)
Yang T
(2020)
A Systematic Analysis of Interactions between Environmental Risk Factors and Genetic Variation in Susceptibility to Colorectal Cancer.
in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Lee H
(2022)
A theory-based practical solution to correct for sex-differential participation bias.
in Genome biology
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |